Breast Cancer
Conditions
Keywords
metastatic breast cancer, metabolomics, biomarkers, Clinical study
Brief summary
RATIONALE: Studying samples of plasm by metabolomics-based approach from women with metastasis breast cancer may help doctors understand the biomarker of visceral metastasis. PURPOSE: This clinical trial is studying the biomarker of visceral metastasis by metabolomics approach in metastasis breast cancer undergoing treatment.
Detailed description
Imaging evaluation of the effect of chemotherapy on patients with visceral metastases from breast cancer, metabolomics was used to analyze the changes of metabolites in plasma, and to find biomarkers that could reflect visceral metastasis and treatment effects. The purpose is to help clinicians predict whether patients have potential visceral metastases, evaluate the effects of visceral metastasis treatment, and reflect the patient's prognosis. Patients with visceral metastases on imaging examinations received chemotherapy as planned, and blood samples were collected from patients before and during imaging assessments. Analysis of metabolites in plasma using ultra high performance liquid chromatography. Patient information were collected through medical record, including race, age, height and body mass index, menarche age, menstrual status, menopausal age (if applicable), tobacco and alcohol history, motherhood history, family history, etc.
Interventions
There is no other intervention, only clinical treatment.
Sponsors
Shandong Cancer Hospital and Institute
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age: 18-70 yrs. * Any menopausal status. * Any hormone receptor status. * Patients must have histologically or imaging confirmed breast cancer with visceral metastatic. * Patients must have measurable disease, per RECIST criteria v1.1.21. * Estimated life expectancy of ≥ 12 weeks. * Ability to swallow oral medications. * Participants must have adequate organ function as defined by: 1. ANC ≥1.5 x 109/L, platelet count ≥100 x 109/L, haemoglobin ≥ 10 g/dL. 2. creatinine \< 1.5 x UNL (upper normal limit). 3. Total bilirubin \< 1.5x UNL. 4. ALT & AST \< 2.5xUNL; alkaline phosphatase \< 2.5xUNL. 5. Creatine phosphokinase (CPK) ≤ 2.5 x UNL. * Patients with CNS metastatic disease are allowed if the disease is controlled and stable for at least 3 months by CT or MRI.
Exclusion criteria
* Current severe, uncontrolled systemic disease (e.g. pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures). * History of other malignancies. * No measureable lesion is present, as defined by RECIST 1.1. * Patients who suffer from a medical or psychiatric condition that, in the opinion of the principal investigator, would impair their ability to participate in the study. * Concurrent interventional studies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolites changes of plasma by High Performance Liquid Chromatography-Mass Spectrometry (LC-MS). | up to six months | To assess the changes of metabolites during the process of our observation, and to find out the relationship between metabolite(s) and therapeutic effect. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression of disease | Up to 10 years | To observe the duration from the stable condition to progression of disease. Patients were followed up every six months in first five years, then followed up once a year. |
| overall survival | Up to 10 years | To observe the duration from the stable condition to death. Patients were followed up every six months in first five years, then followed up once a year. |
Countries
China
Contacts
Primary ContactZhiyong YU, PhD
Backup ContactFukai WANG, MM
Outcome results
None listed